Summary
- Profile Type
- Business Offer
- POD Reference
- BOHU20250203022
- Term of Validity
- 3 February 2025 - 3 February 2026
- Company's Country
- Hungary
- Type of partnership
- Outsourcing agreement
- Targeted Countries
- All countries
Contact the EEN partner nearest to you for more information.
Find my local partner
General information
- Short Summary
- A Budapest, Hungary-based biotechnology research and contract research organization (CRO), specializes in providing in vivo preclinical services. Its expertise includes developing and conducting animal models for testing anticancer therapies and treatments for various other diseases. The SME seeks clients interested in leveraging its services to support their research and development objectives in the frame of outsourcing agreement.
- Full Description
-
A Hungarian biotechnology research and contract research organization (CRO) specializes in in vivo preclinical studies, supporting the development of new drugs and therapies across various disease areas. The SME adheres to the 3Rs principle (replacement, reduction, refinement) to ensure ethical and professional execution of animal-based research, delivering high-quality preclinical data that meets international standards. The services offered include the development and execution of tailored animal models to test the safety and efficacy of drug candidates, with a primary focus on anticancer therapies and treatments for other diseases. These studies are crucial for validating the potential of new compounds before progressing to clinical trials.
The target audience includes pharmaceutical companies (big pharma), small and medium-sized enterprises (SMEs), and academic institutions engaged in drug development and translational research. The company seeks collaborations with international clients and research consortia requiring preclinical services to advance their R&D pipelines. These collaborations aim to accelerate the development of innovative therapies and improve the efficiency of drug discovery processes.
The Hungarian SME aims to build partnerships with big pharma to support large-scale R&D projects, with SMEs to provide cost-effective, customized preclinical solutions, and with universities to foster knowledge exchange and innovation in cutting-edge therapeutic research. For pharmaceutical companies, the organization provides comprehensive preclinical study packages that align with their extensive R&D programs. For SMEs, the focus is on delivering flexible and affordable solutions tailored to their specific objectives. Partnerships with universities emphasize methodological development and academic collaboration to address novel scientific challenges. The SME is offering to perform its services within the frame of outsourcing contract. - Advantages and Innovations
-
The organization specializes in in vivo preclinical studies, offering highly translational oncology models that bridge the gap between early-stage research and clinical trials. While it provides standard xenograft and syngeneic models, its innovative patient-derived tumor xenograft (PDTX) platform stands out by preserving the original tumor microenvironment and improving clinical predictability compared to conventional cell-line xenografts.
The company follows the 3Rs principle, ensuring ethical and scientifically rigorous study execution. Advanced pharmacokinetics and pharmacodynamics models allow for precise dose optimization, and biomarker-based analyses enhance therapeutic targeting.
Collaboration models are structured to meet the specific needs of pharmaceutical companies, SMEs, and academic institutions. Large pharmaceutical companies benefit from comprehensive preclinical study packages, SMEs receive cost-effective, flexible solutions, and academic institutions engage in methodological innovation and translational research partnerships. These capabilities support the development of innovative therapies and improve the efficiency of drug discovery processes. - Sustainable Development Goals
- Goal 3: Good Health and Well-being
- Goal 17: Partnerships to achieve the Goal
Partner Sought
- Expected Role of a Partner
-
The SME provides specialized preclinical research services to pharmaceutical companies, biotechnology SMEs, and academic institutions involved in drug discovery and development. The partnership operates under a contract research model, where the organization delivers tailored preclinical studies, and the partner finances the research. The goal is to generate high-quality, scientifically validated preclinical data that support drug development and regulatory decision-making.
The ideal partners are pharmaceutical companies requiring comprehensive preclinical evaluations, biotechnology SMEs needing flexible and cost-effective research solutions, and academic institutions.
Partners should be active in drug development, pharmacokinetics and pharmacodynamics research, efficacy and safety testing, or innovative preclinical model development. Partners are expected to define project objectives, provide relevant drug candidates and background data, and finance the research according to the agreed study plan.
Collaboration includes joint study design, model selection, and data interpretation to optimize drug development decisions. Research follows scientific and ethical standards, ensuring transparency, reliability, and regulatory compliance. By engaging in this structured partnership, pharmaceutical and biotech companies gain access to advanced preclinical expertise, while academic institutions benefit from methodological development and collaborative knowledge exchange. - Type and Size of Partner
- University
- R&D Institution
- SME 50 - 249
- SME 11-49
- SME <=10
- Big company
- Type of partnership
- Outsourcing agreement
Dissemination
- Market keywords
- 05007002 - Pharmaceuticals/fine chemicals
- 05003001 - Therapeutic services
- 04012 - Toxicology
- Sector Groups Involved
- Health
- Targeted countries
- All countries